Department of Neurology, Kindai University School of Medicine, Osaka-Sayama, Japan; Department of Internal Medicine, Japan Self Defense Forces Hanshin Hospital, Kawanishi, Japan; Division of Neurology, Department of Internal Medicine 3, National Defense Medical College, Tokorozawa, Japan.
Department of Neurology, Kindai University School of Medicine, Osaka-Sayama, Japan.
J Neuroimmunol. 2018 Oct 15;323:131-135. doi: 10.1016/j.jneuroim.2018.08.007. Epub 2018 Aug 18.
We evaluated the effects of a non-specific potassium channel blocker, 4-aminopyridine (4-AP), on chronic experimental autoimmune encephalomyelitis (chEAE) and relapsing remitting EAE (rrEAE) in mice. 4-AP did not affect chEAE, but ameliorated rrEAE, particularly in the relapsing phase. Disease amelioration was confirmed pathologically, and glial fibrillary acidic protein expression was observed to be downregulated in 4-AP-treated mice. In the recall response, a T-cell proliferative response was not inhibited; however, Th1/Th17 polarization was attenuated. 4-AP is currently accepted as an anti-symptomatic drug only in the chronic phase of multiple sclerosis (MS); however, its use in the active phase of MS should be considered.
我们评估了非特异性钾通道阻滞剂 4-氨基吡啶（4-AP）对慢性实验性自身免疫性脑脊髓炎（chEAE）和复发性缓解性 EAE（rrEAE）在小鼠中的作用。4-AP 对 chEAE 没有影响，但改善了 rrEAE，特别是在复发期。疾病改善得到了病理证实，并且在 4-AP 处理的小鼠中观察到神经胶质纤维酸性蛋白表达下调。在回忆反应中，T 细胞增殖反应没有被抑制；然而，Th1/Th17 极化被减弱。4-AP 目前仅在多发性硬化症（MS）的慢性期被认为是一种对症药物；然而，应该考虑在 MS 的活动期使用它。
